

Amprenavir

Catalog No: tcsc1410



Available Sizes

Size: 5mg

Size: 25mg

Size: 50mg



Specifications

CAS No:

161814-49-9

Formula:

$C_{25}H_{35}N_3O_6S$

Pathway:

Metabolic Enzyme/Protease;Anti-infection

Target:

HIV Protease;HIV

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 100 mg/mL (197.77 mM)

Alternative Names:

VX-478

Observed Molecular Weight:

505.63

Product Description


Amprenavir (VX-478) is a HIV protease inhibitor($K_i=0.6$ nM) used to treat HIV infection.

IC50 & Target: IC50 Value: 0.6 nM (K_i); Against wild-type clinical HIV isolates:14.6 +/- 12.5 ng/mL (mean +/- SD) [1].

Target: HIV protease

In Vitro: Amprenavir has an enzyme inhibition constant ($K_i = 0.6$ nM) that falls within the K_i range of the other protease inhibitors. Amprenavir's in vitro 50% inhibitory concentration (IC50) against wild-type clinical HIV isolates is 14.6 +/- 12.5 ng/mL (mean +/- SD) [1]. Amprenavir had direct inhibitory effects on invasion of Huh-7 hepatocarcinoma cell lines, inhibiting MMP proteolytic activation [2].

In Vivo: Amprenavir was able to promote regression of hepatocarcinoma growth in vivo by anti-angiogenetic and overall anti-tumor activities, independently by PI3K/AKT related pathways that at today is one of the more suggestive hypothesis to explain the anti-tumor effects of the different protease inhibitors [2]. Amprenavir efficiently activated PXR and induced PXR target gene expression in vitro and in vivo. Short-term exposure to amprenavir significantly increased plasma total cholesterol and atherogenic low-density lipoprotein cholesterol levels in wild-type mice, but not in PXR-deficient mice [3]. Amprenavir has been approved for adults and children; the recommended capsule doses are 1200 mg twice daily for adults and 20 mg/kg twice daily or 15 mg/kg 3 times daily for children



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!